Live Biotherapeutics Products and Microbe CDMO Market is Expected to Grow at a High CAGR Through 2028
Increasing awareness of the importance of
microbiome and initiatives taken by government to improve the healthcare
infrastructure in their respective country are the major drivers for the global live biotherapeutics products and microbe CDMO market.
According to TechSci Research
report, “Global Live Biotherapeutics Products and Microbe CDMO Market – Industry Size, Share, Trends, Competition,
Opportunity and Forecast, 2018-2028”, the global live
biotherapeutics products and microbe CDMO market is anticipated to register a
high CAGR during the forecast period. This can be ascribed to growth in technological
advancements associated with enhancement in properties of live biotherapeutic
products and microbe CDMO.
The microbiome refers to
the collection of microorganisms that live on and inside the human body.
Increasing research has shown that the microbiome plays a crucial role in
maintaining human health and preventing disease. This has led to an increased
awareness of the importance of the microbiome, which has in turn driven the
growth of the global live biotherapeutics products and microbe CDMO market.
Live biotherapeutics products are designed to restore and maintain the balance
of the microbiome and treat a variety of diseases. Rise in understanding of
microbiome have increased the demand of live biotherapeutic products (LBPs),
which is further expected to propel the growth of the market in the forecast
period.
Moreover, the growth in
technological advancements is also one of the significant drivers of global
live biotherapeutics products and microbe CDMO market. One recent technological
development in the global live biotherapeutics products (LBPs) market is the
use of synthetic biology to engineer specific strains of bacteria that can produce
therapeutic molecules. This approach allows for more precise control over the
therapeutic effects of LBPs and could lead to the development of more effective
treatments for a variety of conditions. Another development associated with
microbe CDMO (contract development and manufacturing organization) is the use
of automation and artificial intelligence to improve the efficiency and speed
of the drug development and manufacturing process. This includes the use of
robotic systems for high-throughput screening of microbial strains and the use
of machine learning algorithms to optimize fermentation conditions for maximum
yield and productivity. Another major advancement in the microbe CDMO market is
the growing use of continuous manufacturing processes, which allow for more
consistent and efficient production of microbial products compared to
traditional batch processes. Growth in geriatric population across the world is
expected to register an impressive growth to global live biotherapeutics
products and microbe CDMO market in the forecast period. Some of the common
chronic diseases which affect people after 65 years of age include arthritis
and joints problem, hypertension, cardiovascular diseases, diabetes,
osteoporosis, cancer, and others. According to the report published by
Centers for Disease Control and Prevention, it has been observed that around
10.9% of adults in the world aged above 45 years of age get diagnosed with
coronary heart diseases every year. Among which 7.1% of people are between
45-64 years of age and 17.0% of them are either 65 years old or above.
Moreover, the prevalence of coronary heart diseases varied among ethnic groups,
where 11.4% of them were whites, 10.0% were Black/African Americans and 6.3% of
them were Asians and Pacific Islanders. Rising mortality rate of elderly
people, caused due to chronic diseases is further increasing the demand of live
biotherapeutics products and microbe CDMO. Furthermore, initiatives taken by
government to improve the quality of medical facilities for people along with the
implementation of new healthcare policies and health insurance plans are
expected to register a lucrative growth to global live biotherapeutics products
and microbe CDMO market in forthcoming years.
However, regulatory
challenges, limited understanding of human microbiome among people, lack of
standardization, and high development and manufacturing costs of live
biotherapeutics products are expected to slow down the growth of the market in
the coming years.
Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on "Global
Live Biotherapeutics Products and Microbe CDMO Market”
The Global live biotherapeutics products and microbe CDMO market segmentation
is based on application, product, type of formulation, scale of operation, by
company, and region.
Based on type of
formulation, the market is further divided into solid formulations, oral
liquids, injectables, and others. Oral liquids are likely to dominate the
market in the forecast period. This can be ascribed to its
affordable price and easy availability in the market.
Some of the major
companies operating in the global live biotherapeutics products and microbe CDMO
market include:
- Arranta Bio
Holdings LLC.
- 4D Pharma
plc.
- Cerbios-Pharma
S.A.
- Biose Industrie
- Assembly
Biosciences, Inc.
- Wacker Chemie AG
- Quay
Pharmaceuticals Ltd.
- Bacthera AG
- LONZA
- Inpac Probiotics
Download Free Sample Report
Customers can also request for 10% free customization on
this report.
“Certain regions are expected to dominate the demand for live
biotherapeutics products and microbe CDMO in the world. Establishments of
various hospitals and medical centers across various developing countries of
the world which are increasing the availability of live biotherapeutics
products among people are expected to register an impressive growth in global live biotherapeutics
products and microbe CDMO market in the forecast period," said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based Global management consulting
firm.
Live Biotherapeutics Products and Microbe CDMO
Market - Global Industry Size, Share, Trends, Competition, Opportunity, and
Forecast, 2018-2028 Segmented By Application (C.difficle, Crohns disease, IBS,
Diabetes, and Others), By Product (APIs, FDFs), By Type of Formulation (Solid
Formulations, Oral Liquids, Injectables, and Others), By Scale of Operation
(Preclinical Scale Operations, Clinical Scale Operations, and Commercial Scale
Operations), By Region and Competition”, has evaluated the future
growth potential of global live biotherapeutics products and microbe CDMO market
and provides statistics & information on market size, structure, and future
market growth. The report intends to provide innovative market intelligence and
help decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in global live biotherapeutics products and
microbe CDMO market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Web: https://www.techsciresearch.com